200 related articles for article (PubMed ID: 33411765)
1. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
Jubair L; Lam AK; Fallaha S; McMillan NAJ
PLoS One; 2021; 16(1):e0223288. PubMed ID: 33411765
[TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.
Zhen S; Li X
Cell Physiol Biochem; 2017; 44(6):2455-2466. PubMed ID: 29268281
[TBL] [Abstract][Full Text] [Related]
5. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout.
Zhen S; Lu J; Liu YH; Chen W; Li X
Cancer Gene Ther; 2020 Apr; 27(3-4):168-178. PubMed ID: 31455836
[TBL] [Abstract][Full Text] [Related]
7. Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors.
Jubair L; Fallaha S; McMillan NAJ
Mol Ther; 2019 Dec; 27(12):2091-2099. PubMed ID: 31537455
[TBL] [Abstract][Full Text] [Related]
8. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells.
Hu Z; Yu L; Zhu D; Ding W; Wang X; Zhang C; Wang L; Jiang X; Shen H; He D; Li K; Xi L; Ma D; Wang H
Biomed Res Int; 2014; 2014():612823. PubMed ID: 25136604
[TBL] [Abstract][Full Text] [Related]
9. The application of CRISPR/Cas9 system in cervical carcinogenesis.
Gao C; Wu P; Yu L; Liu L; Liu H; Tan X; Wang L; Huang X; Wang H
Cancer Gene Ther; 2022 May; 29(5):466-474. PubMed ID: 34349239
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy.
Zhu D; Shen H; Tan S; Hu Z; Wang L; Yu L; Tian X; Ding W; Ren C; Gao C; Cheng J; Deng M; Liu R; Hu J; Xi L; Wu P; Zhang Z; Ma D; Wang H
Mol Ther; 2018 Oct; 26(10):2443-2455. PubMed ID: 30241742
[TBL] [Abstract][Full Text] [Related]
12. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
Cheng X; Fan S; Wen C; Du X
Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.
Zhen S; Hua L; Takahashi Y; Narita S; Liu YH; Li Y
Biochem Biophys Res Commun; 2014 Aug; 450(4):1422-6. PubMed ID: 25044113
[TBL] [Abstract][Full Text] [Related]
17. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
J Pathol; 2018 Feb; 244(2):151-163. PubMed ID: 28944962
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of specific and efficient CRISPR/Cas9 system targeting HPV16 oncogenes using LL-37 antimicrobial peptide in C57BL/6 mice.
Khairkhah N; Bolhassani A; Rajaei F; Najafipour R
J Med Virol; 2023 Jul; 95(7):e28934. PubMed ID: 37403986
[TBL] [Abstract][Full Text] [Related]
20. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]